http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View More Recent Stories
-
Jaguar Health Announces New Employee Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
-
Jaguar Health (JAGX) Issued New US Patent
-
Issuance of New US Patent Bolsters IP Protection for Jaguar Health in the Treatment of Congenital Diarrheal Disorders (CDDs)
-
Jaguar Health (JAGX) Reports Majority of Subjects in Phase 3 OnTarget Trial for Prophylaxis of Diarrhea in Adult Cancer Patients Receiving Targeted Therapy Chose to Continue on to Stage II
-
A Majority of Subjects in Jaguar Health's Placebo-Controlled Pivotal Phase 3 OnTarget Trial for Prophylaxis of Diarrhea in Adult Cancer Patients Receiving Targeted Therapy Chose to Continue on to Stag
-
MASCC (Multinational Association of Supportive Care in Cancer) Webinar on GI Toxicities from Cancer Therapies Made Possible by Grant From Napo Pharmaceuticals, a Jaguar Health Family Company
-
Study Data on Quality of Life for Breast Cancer Patients and Survivors, Supported by Napo Pharmaceuticals (a Jaguar Health Family Company), Published on San Antonio Breast Cancer Symposium (SABCS) Web
-
Jaguar Health (JAGX) Announces FDA Approves Renewal of Canalevia-CA1, its Drug for Chemotherapy-Induced Diarrhea in Dogs
-
FDA Approves Renewal of Canalevia-CA1, Jaguar Health’s Drug for Chemotherapy-Induced Diarrhea in Dogs
-
Jaguar Health to Present December 5 at the MedInvest Oncology Investor Conference
-
Jaguar Health Reports Third Quarter 2023 Financial Results
-
Jaguar Health Announces New Employee Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
-
Breast Cancer Related Results of Groundbreaking Napo Pharmaceuticals (a Jaguar Health Family Company) Supported Study on Quality of Life for Cancer Patients and Survivors Accepted for Presentation at
-
Jaguar Health (JAGX) Receives Additional 180-day Grace Period to Regain Compliance with Nasdaq's Bid Price Rule
-
Jaguar Health Receives Additional 180-day Grace Period to Regain Compliance with Nasdaq's Bid Price Rule
-
Jaguar Health to Hold Investor Webcast Tuesday, November 14th at 8:30 AM Eastern Regarding Q3 2023 Financials & Corporate Updates
-
REMINDER: Jaguar Health to Host Virtual Educational Webinar on Rare Intestinal Failure Diseases with Leading Gastroenterologists and Nutrition Experts November 8th from 1:00 PM to 2:30 PM EST
-
Jaguar Health Enters Exclusive Crofelemer Revenue Sharing License and Commercialization Agreement with Quadri Pharmaceuticals Store for Rare Intestinal Failure Diseases in Middle East Markets
-
Issuance of New US Patent Bolsters IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome (SBS)
-
Presenting on the Emerging Growth Conference 64 Day 1 on November 1 Register Now
-
Magdalena Biosciences, a Joint Venture between Jaguar Health and Filament Health, Receives Second Tranche of Funding from One Small Planet
-
Jaguar Health to Present November 1st at Emerging Growth Conference
-
Magdalena Biosciences Initiates Preclinical Study to Evaluate Plant Extracts to Treat Depression, Anxiety, ADHD and Other Mental Health Indications
-
Independent Study Conducted at Boston Children's Hospital, Harvard Medical School, Shows Potential Utility of Jaguar Health's Crofelemer for Treatment of MVID, a Rare Childhood Disease
-
Napo Pharmaceuticals to Exhibit at the October 25-28 Annual Association of Nurses in AIDS Care (ANAC) Conference for Mytesi, the Company’s FDA-Approved Prescription Drug
-
Jaguar Health to Present October 17 at the Lytham Partners Fall 2023 Investor Conference and October 18 at the BIO Investor Forum
-
Jaguar Animal Health Exhibiting at October 12-14 VCS Annual Conference for Canalevia-CA1, the Company's FDA Conditionally Approved Drug for Chemotherapy-Induced Diarrhea (CID) in Dogs
-
Napo Pharmaceuticals Supports Groundbreaking Study on Quality of Life for Cancer Patients and Survivors
-
Jaguar Health Announces Import of Coca Leaf From Peru by Joint Venture Magdalena Biosciences for Research in Treating ADHD
-
Jaguar Health Shares Presentation Replay Link from September 11-13, 2023 H.C. Wainwright Annual Global Investment Conference
-
Jaguar Health (JAGX) Receives Japan Patent for Treatment of Short Bowel Syndrome
-
Patent Issued in Japan Bolsters IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome (SBS)
-
Jaguar Health Shares Replay Link for September 7, 2023 Presentation at Emerging Growth Conference
-
Jaguar Health's Executive VP Dr. Karen Brunke Joins BIO's Rare Disease and Orphan Drugs Committee
-
Presenting on the Emerging Growth Conference on September 6 and 7 Register Now
-
Jaguar Health (JAGX) Reports Publications on Developing Crofelemer for Two Rare Disease Indications
-
The Science Times Publishes Article About Jaguar Health's Focus on Developing Crofelemer for Two Rare Disease Indications
-
Jaguar Health Engages B2i Digital to Deploy Cutting-Edge Investor Engagement Campaign
-
Presenting on the Emerging Growth Conference on August 9 & 10 Register Now
-
Canine and Child Cancer Research Advocates Call for Support as Capitol Hill "Goes to the Dogs"
-
Jaguar Health Announces Establishment of Board of Directors for Newly Formed Joint Venture Magdalena Biosciences
-
Jaguar Health (JAGX) and Filament Health Funded by One Small Planet form FV for Drug Candidates for Mental Health Illnesses
-
Jaguar Health and Filament Health, with Funding from One Small Planet, Form Joint Venture Magdalena Biosciences to Develop Botanical Pharmaceutical Drug Candidates for Mental Health Illnesses
-
Jaguar Health and Filament Health Sign Letter of Intent to Develop Botanical Prescription Drugs for Specific Mental Health Indications
-
Jaguar Health Subsidiary Napo Pharmaceuticals Launches National “Keep Your Pants On… Unless You Don’t Want To” Campaign to Highlight the Need to Recognize and Treat Diarrhea in People Living W
-
Jaguar and Napo Issue Commercial Updates
-
Pre-Open Stock Movers 10/06: (ALQA) (SCYX) (ZUMZ) Higher; (ALNY) (TWTR) (MDCO) Lower (more...)
